Efficacy of Trametinib in Neurofibromatosis Type 1-Associated Gastrointestinal Stromal Tumors: A Case Report.

Fukuda, Misao; Mukohara, Toru; Kuwata, Takeshi; Sunami, Kuniko; Naito, Yoichi

Fukuda, Misao; Mukohara, Toru; Kuwata, Takeshi; Sunami, Kuniko; Naito, Yoichi.

Afiliación

Fukuda M; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Mukohara T; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Kuwata T; Department of Genetic Medicine and Services, National Cancer Center Hospital East, Kashiwa, Japan.
Sunami K; Department of Genetic Medicine and Services, National Cancer Center Hospital East, Kashiwa, Japan.
Naito Y; Department of Laboratory Medicine, National Cancer Center Hospital, Tokyo, Japan.

JCO Precis Oncol ; 8: e2300649, 2024 Aug.

Article en En | MEDLINE | ID: mdl-39116355

ABSTRACT

ABSTRACT

Trametinib, an MEK inhibitor, may offer a new therapeutic option for patients with NF1-related GIST.

Asunto(s)

Tumores del Estroma Gastrointestinal; Neurofibromatosis 1; Piridonas; Pirimidinonas; Humanos; Piridonas/uso terapéutico; Tumores del Estroma Gastrointestinal/tratamiento farmacológico; Pirimidinonas/uso terapéutico; Neurofibromatosis 1/tratamiento farmacológico; Neurofibromatosis 1/complicaciones; Masculino; Femenino; Persona de Mediana Edad; Inhibidores de Proteínas Quinasas/uso terapéutico; Neoplasias Gastrointestinales/tratamiento farmacológico; Antineoplásicos/uso terapéutico

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Piridonas / Pirimidinonas / Neurofibromatosis 1 / Tumores del Estroma Gastrointestinal Límite: Female / Humans / Male / Middle aged Idioma: En Revista: JCO Precis Oncol Año: 2024 Tipo del documento: Article País de afiliación: Japón

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google